Author:
Papamichael Konstantinos,Afif Waqqas,Drobne David,Dubinsky Marla C,Ferrante Marc,Irving Peter M,Kamperidis Nikolaos,Kobayashi Taku,Kotze Paulo G,Lambert Jo,Noor Nurulamin M,Roblin Xavier,Roda Giulia,Vande Casteele Niels,Yarur Andres J,Arebi Naila,Danese Silvio,Paul Stephane,Sandborn William J,Vermeire Séverine,Cheifetz Adam S,Peyrin-Biroulet Laurent
Funder
National Institutes of Health
Subject
Gastroenterology,Hepatology
Reference175 articles.
1. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases;Papamichael;Expert Rev Clin Immunol,2019
2. Therapeutic drug monitoring of biologics during induction to prevent primary non-response;Sparrow;J Crohn's Colitis,2020
3. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease;Fine;Gastroenterol Hepatol (NY),2019
4. Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease;McNeill;Curr Opin Pharmacol,2020
5. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared with reactive and clinical monitoring;Syed;Crohns Colitis 360,2020
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献